Barclays PLC Makes New $1.45 Million Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Barclays PLC bought a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 74,583 shares of the company's stock, valued at approximately $1,446,000. Barclays PLC owned approximately 0.21% of Oruka Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after acquiring an additional 1,572,853 shares during the period. Franklin Resources Inc. bought a new position in Oruka Therapeutics during the third quarter worth about $17,661,000. Geode Capital Management LLC acquired a new position in Oruka Therapeutics during the third quarter worth approximately $343,000. Wellington Management Group LLP raised its stake in Oruka Therapeutics by 15.8% in the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock valued at $1,844,000 after buying an additional 12,952 shares during the period. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $303,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Price Performance

NASDAQ:ORKA traded down $0.69 during trading hours on Tuesday, hitting $9.29. The stock had a trading volume of 227,535 shares, compared to its average volume of 233,645. The firm has a market capitalization of $347.83 million, a price-to-earnings ratio of -1.48 and a beta of 0.25. The company has a 50 day simple moving average of $9.98 and a two-hundred day simple moving average of $15.93. Oruka Therapeutics, Inc. has a one year low of $5.49 and a one year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.19. Equities research analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on ORKA shares. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, February 7th. Wedbush reaffirmed an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a report on Friday, March 7th. Finally, Wolfe Research started coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $39.86.

Insider Transactions at Oruka Therapeutics

In related news, major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was purchased at an average price of $11.44 per share, with a total value of $1,015,803.36. Following the completion of the purchase, the insider now owns 4,148,428 shares of the company's stock, valued at approximately $47,458,016.32. The trade was a 2.19 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders purchased 98,339 shares of company stock worth $1,128,456 in the last three months. Corporate insiders own 22.67% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.